As current standard of care, treatment options are typically selected based on a few clinical markers like cancer stage, the presence or absence of hormone receptors, HER2/neu amplification and the menopausal status of the patient (https://www.cancer.org/cancer/breast-cancer/treatment/treatment-of-breast-cancer-by-stage.html). Here, ERBB2 is linked to cancer.